Jin Wei, Zhao Zichong, Zhou Dongping
Wei Jin, Department of Paediatrics, Huzhou Maternity & Child Health Care Hospital, Huzhou 313000, Zhejiang Province, P.R. China.
Zichong Zhao, Department of Paediatrics, Huzhou Maternity & Child Health Care Hospital, Huzhou 313000, Zhejiang Province, P.R. China.
Pak J Med Sci. 2022 May-Jun;38(5):1265-1270. doi: 10.12669/pjms.38.5.5749.
To investigate the effects of Montelukast sodium combined with Budesonide aerosol on airway function and T lymphocytes in asthmatic children.
The records of 86 pediatric asthma patients, treated in Huzhou Maternal and Child Health Hospital from February 2020 to March 2021, were studied retrospectively. Of them, 40 children received routine treatment + budesonide atomizer (Group-I), and 46 patients received routine treatment + budesonide atomizer + montelukast sodium (Group-II). The improvement in airway and lung function, and T-lymphocyte count in both groups after 3 months of corresponding treatment were analyzed.
After three months of treatment, expiratory flow rate (TEF) with the tidal volume of 25%, 50% and 75%, was significantly higher in Group-II than Group-I (P<0.05). CD8+ expression in Group-II was lower, and CD3+, CD4+ and CD4+/CD8+ were higher than those in Group-I (P<0.05). There was a significant difference in the levels of inflammatory factors between the two groups. The levels of IL-4, IL-5 and IFN-γ in Group-II were lower than those in Group-I(P<0.05).
In the clinical treatment of asthmatic children, in combination with routine treatment, budesonide atomizer and montelukast sodium can effectively promote the improvement of airway function, regulate T lymphocytes levels, reduce inflammatory reaction and improve the total clinical curative effect.
探讨孟鲁司特钠联合布地奈德气雾剂对哮喘患儿气道功能及T淋巴细胞的影响。
回顾性分析2020年2月至2021年3月在湖州市妇幼保健院治疗的86例小儿哮喘患者的病历资料。其中,40例患儿接受常规治疗+布地奈德雾化器(I组),46例患者接受常规治疗+布地奈德雾化器+孟鲁司特钠(II组)。分析两组在相应治疗3个月后气道和肺功能的改善情况以及T淋巴细胞计数。
治疗3个月后,II组在潮气量为25%、50%和75%时的呼气流量(TEF)显著高于I组(P<0.05)。II组CD8+表达较低,CD3+、CD4+和CD4+/CD8+高于I组(P<0.05)。两组炎症因子水平存在显著差异。II组IL-4、IL-5和IFN-γ水平低于I组(P<0.05)。
在小儿哮喘的临床治疗中,联合常规治疗,布地奈德雾化器和孟鲁司特钠可有效促进气道功能改善,调节T淋巴细胞水平,减轻炎症反应,提高临床总疗效。